{"id":391414,"date":"2015-04-28T00:00:00","date_gmt":"2015-04-28T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dbasid0215-biopharma-hepatitis-c-virus-treatment-experienced-cirrhotic-decision-base-us-2015\/"},"modified":"2026-04-14T10:29:08","modified_gmt":"2026-04-14T10:29:08","slug":"dbasid0215-biopharma-hepatitis-c-virus-treatment-experienced-cirrhotic-decision-base-us-2015","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dbasid0215-biopharma-hepatitis-c-virus-treatment-experienced-cirrhotic-decision-base-us-2015\/","title":{"rendered":"Hepatitis C Virus (Treatment-Experienced, Cirrhotic) | Decision Base | US | 2015"},"content":{"rendered":"<p><em>How Will New Market Entrants Fare in the Rapidly Evolving Treatment Landscape?<\/em><\/p>\n<p>Affecting at least 170 million people worldwide, chronic hepatitis C virus (HCV) infections are a serious public health problem. Among patients with chronic HCV infections, those who have failed prior HCV therapy (i.e., treatment-experienced) and\/or have advanced liver disease (cirrhosis) have been historically considered a difficult-to-treat patient subgroup. However, the growing availability of safe and highly effective interferon (IFN)-free regimens consisting of direct-acting antivirals (DAAs) has essentially equalized outcomes for treatment-experienced cirrhotics with those of treatment-naive, non-cirrhotic HCV patients. Despite the significant advantages offered by new treatment options for HCV, there remains high unmet need for more effective options for genotype-3 patients with cirrhosis. Further, extensive payer-imposed cost-containment measures have limited widespread access to these new therapies, and, as such, cost-effective options for treatment-experienced, cirrhotic HCV patients is another area of high unmet need.<\/p>\n","protected":false},"template":"","class_list":["post-391414","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-hepatitis-c-virus","biopharma-geography-us","biopharma-date-717"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391414","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391414\/revisions"}],"predecessor-version":[{"id":394537,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391414\/revisions\/394537"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=391414"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}